Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Critical Issues in Treating HIV During Pregnancy

Landsberger1

  • 1High-Risk Obstetrics Clinic at The New York Hospital-Cornell Medical Center, New York City, NY.

Medscape Women'S Health
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ground-state photoneutron reactions in 14C.

Physical review. C, Nuclear physics·1985
Same author

High spin states in 99Tc.

Physical review. C, Nuclear physics·1985
See all related articles

Zidovudine (AZT) significantly reduces perinatal HIV transmission by two-thirds when administered to mothers during pregnancy and labor, and to newborns. This treatment is crucial for preventing mother-to-child HIV transmission.

Area of Science:

  • Virology
  • Obstetrics
  • Public Health

Background:

  • HIV infection in pregnant women presents unique challenges for transmission prevention.
  • Understanding the timing and mechanisms of vertical HIV transmission is critical for intervention.
  • Maternal HIV viral load is a key predictor of perinatal transmission risk.

Purpose of the Study:

  • To evaluate the efficacy of zidovudine (AZT) in reducing perinatal HIV transmission.
  • To investigate the impact of pregnancy on HIV progression.
  • To explore the relationship between maternal viral load and HIV transmission.

Main Methods:

  • Administration of zidovudine (AZT) to HIV-infected pregnant women during pregnancy and labor.
  • Administration of zidovudine (AZT) to newborns for six weeks post-delivery.

Related Experiment Videos

  • Monitoring of maternal and infant HIV status and viral load.

    • Main Results:

    • Zidovudine (AZT) regimen reduced perinatal HIV transmission by two-thirds.
    • Pregnancy was not found to accelerate HIV progression.
    • Vertical HIV transmission can occur as early as 8 weeks gestation.
    • Maternal HIV resistance to zidovudine can lead to transmission of resistant strains.
    • High maternal viral load (>80,000 RNA copies/mL) correlated with 100% transmission, while low viral load (<20,000 copies/mL) correlated with 0% transmission.
    • Zidovudine treatment led to an 8-fold median decrease in plasma RNA levels.

    Conclusions:

    • The zidovudine (AZT) regimen is highly effective in preventing mother-to-child HIV transmission.
    • Maternal viral load is a critical factor in predicting transmission risk.
    • Monitoring viral load and managing zidovudine resistance are important components of perinatal HIV prevention.